Comparative Pharmacology
Head-to-head clinical analysis: PACERONE versus QUINIDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PACERONE versus QUINIDEX.
PACERONE vs QUINIDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs action potential duration and refractory period by blocking potassium channels, and also exhibits class I, II, and IV effects.
Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.
Loading dose: 800-1600 mg/day PO in divided doses for 1-3 weeks, then 600-800 mg/day PO for 1 month; maintenance: 200-400 mg/day PO once daily. IV: 150 mg over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min.
Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.
None Documented
None Documented
Biphasic: initial 3-10 days; terminal elimination half-life 40-58 days (mean ~53 days) due to extensive tissue distribution and slow release from fat. Clinical context: steady-state achieved in 2-4 months without loading dose.
Terminal elimination half-life is 6-8 hours in adults with normal renal and hepatic function; may be prolonged to 10-12 hours in congestive heart failure or hepatic impairment.
Primarily hepatic metabolism (CYP3A4, CYP2C8) to desethylamiodarone (active). Renal elimination of drug and metabolites: <1% of unchanged drug; ~40% of dose as metabolites. Fecal elimination: ~70% of dose as metabolites, with some parent drug.
Renal excretion accounts for approximately 20% unchanged drug; hepatic metabolism (primarily CYP3A4) accounts for 80% with metabolites excreted renally and biliarily; about 5% excreted in feces.
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent